Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Baljevic, M., Campagnaro, E., Castillo, J. J., Costello, C., D'Angelo, C., Devarakonda, S., Elsedawy, N., Garfall, A., Godby, K., Hillengass, J., Holmberg, L., Htut, M., Huff, C. A., Hultcrantz, M., Kang, Y., Larson, S., Lee, H. C., Liedtke, M., Martin, T., Omel, J., Rosenberg, A., Sborov, D., Valent, J., Berardi, R., Kumar, R. 2023; 21 (1): 67-81

Abstract

Primary systemic light chain amyloidosis (SLCA) is characterized by production of light chains that get converted to amyloid fibrils with an affinity for visceral organs and causing organ dysfunction. The therapy for SLCA is directed to recovering the function of the affected organs by targeting the abnormal plasma cell clone and slowing deposition of amyloid fibrils. The NCCN Guidelines for SLCA provide recommendations for workup, diagnosis, and treatment of primary as well as previously treated SLCA.

View details for DOI 10.6004/jnccn.2023.0001

View details for PubMedID 36652935